{"name":"UCB Pharma","slug":"ucb-pharma","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-11-30","label":"Niravam Phase 3 readout (Stereotypical Prolonged Seizures)","drug":"Niravam","drugSlug":"niravam","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":12,"colorKey":"oncology","drugs":[{"name":"Alprazolam orally disintegrating tablets","genericName":"Alprazolam orally disintegrating tablets","slug":"alprazolam-orally-disintegrating-tablets","indication":"Anxiety disorders","status":"phase_3"},{"name":"Brivaracetam (ucb 34714)","genericName":"Brivaracetam (ucb 34714)","slug":"brivaracetam-ucb-34714","indication":"Adjunctive treatment of partial-onset seizures in epilepsy","status":"phase_3"},{"name":"Brivaracetam bolus","genericName":"Brivaracetam bolus","slug":"brivaracetam-bolus","indication":"Adjunctive treatment of partial-onset seizures in patients with epilepsy","status":"phase_3"},{"name":"Brivaracetam infusion","genericName":"Brivaracetam infusion","slug":"brivaracetam-infusion","indication":"Adjunctive treatment of partial-onset seizures in patients with epilepsy","status":"phase_3"},{"name":"Keppra XR (Levetiracetam XR)","genericName":"Keppra XR (Levetiracetam XR)","slug":"keppra-xr-levetiracetam-xr","indication":"Adjunctive therapy for partial-onset seizures in epilepsy","status":"phase_3"},{"name":"Keppra® extended release formulation - XR","genericName":"Keppra® extended release formulation - XR","slug":"keppra-extended-release-formulation-xr","indication":"Adjunctive therapy for partial-onset seizures","status":"phase_3"},{"name":"Levetiracetam (Keppra)","genericName":"Levetiracetam (Keppra)","slug":"levetiracetam-keppra","indication":"Partial-onset seizures (adjunctive therapy)","status":"marketed"},{"name":"Methylphenidate Extended Release Capsules","genericName":"Methylphenidate Extended Release Capsules","slug":"methylphenidate-extended-release-capsules","indication":"Attention-deficit/hyperactivity disorder (ADHD) in children and adults","status":"marketed"},{"name":"Neupro®","genericName":"Neupro®","slug":"neupro","indication":"Parkinson's disease (early-stage and advanced)","status":"marketed"},{"name":"SPM 927","genericName":"SPM 927","slug":"spm-927","indication":"Epilepsy (focal seizures)","status":"phase_3"},{"name":"SPM 929","genericName":"SPM 929","slug":"spm-929","indication":"Major depressive disorder","status":"phase_3"},{"name":"SSRI/SNRI","genericName":"SSRI/SNRI","slug":"ssri-snri","indication":"Major depressive disorder","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":10,"colorKey":"immunology","drugs":[{"name":"CDP6038","genericName":"CDP6038","slug":"cdp6038","indication":"Other","status":"phase_2"},{"name":"CDP7657","genericName":"CDP7657","slug":"cdp7657","indication":"Other","status":"phase_1"},{"name":"Cetirizine tablets","genericName":"Cetirizine tablets","slug":"cetirizine-tablets","indication":"Allergic rhinitis (seasonal and perennial)","status":"marketed"},{"name":"Kemstro","genericName":"Kemstro","slug":"kemstro","indication":"Other","status":"marketed"},{"name":"Levocetirizine (drug)","genericName":"Levocetirizine (drug)","slug":"levocetirizine-drug","indication":"Allergic rhinitis (seasonal and perennial)","status":"marketed"},{"name":"Levocetirizine oral solution","genericName":"Levocetirizine oral solution","slug":"levocetirizine-oral-solution","indication":"Allergic rhinitis (seasonal and perennial)","status":"marketed"},{"name":"Levocetirizine tablets","genericName":"Levocetirizine tablets","slug":"levocetirizine-tablets","indication":"Allergic rhinitis","status":"phase_2"},{"name":"Niravam","genericName":"Niravam","slug":"niravam","indication":"Other","status":"marketed"},{"name":"Placebo-Cetirizine","genericName":"Placebo-Cetirizine","slug":"placebo-cetirizine","indication":"Allergic rhinitis","status":"phase_3"},{"name":"Placebo-Levocetirizine","genericName":"Placebo-Levocetirizine","slug":"placebo-levocetirizine","indication":"Allergic rhinitis","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"Certolizumab Pegol (CZP)","genericName":"Certolizumab Pegol (CZP)","slug":"certolizumab-pegol-czp","indication":"Rheumatoid arthritis","status":"marketed"},{"name":"Certolizumab pegol (CDP870)","genericName":"Certolizumab pegol (CDP870)","slug":"certolizumab-pegol-cdp870","indication":"Rheumatoid arthritis","status":"phase_3"},{"name":"Placebo + Methotrexate (MTX)","genericName":"Placebo + Methotrexate (MTX)","slug":"placebo-methotrexate-mtx","indication":"Rheumatoid arthritis","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Cetirizine drops","genericName":"Cetirizine drops","slug":"cetirizine-drops","indication":"Allergic rhinitis (seasonal and perennial)","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Placebo to Pentoxifylline oral","genericName":"Placebo to Pentoxifylline oral","slug":"placebo-to-pentoxifylline-oral","indication":"Intermittent claudication (peripheral arterial disease)","status":"phase_3"}]}],"pipeline":[{"name":"Alprazolam orally disintegrating tablets","genericName":"Alprazolam orally disintegrating tablets","slug":"alprazolam-orally-disintegrating-tablets","phase":"phase_3","mechanism":"Alprazolam is a benzodiazepine that enhances the inhibitory effects of GABA at the GABA-A receptor, reducing neuronal excitability and producing anxiolytic and sedative effects.","indications":["Anxiety disorders","Panic disorder","Anxiety associated with depression"],"catalyst":""},{"name":"Brivaracetam (ucb 34714)","genericName":"Brivaracetam (ucb 34714)","slug":"brivaracetam-ucb-34714","phase":"phase_3","mechanism":"Brivaracetam binds to synaptic vesicle protein 2A (SV2A) to reduce neuronal excitability and prevent seizures.","indications":["Adjunctive treatment of partial-onset seizures in epilepsy","Generalized tonic-clonic seizures (pipeline indication)"],"catalyst":""},{"name":"Brivaracetam bolus","genericName":"Brivaracetam bolus","slug":"brivaracetam-bolus","phase":"phase_3","mechanism":"Brivaracetam is a selective synaptic vesicle protein 2A (SV2A) ligand that modulates neurotransmitter release to reduce seizure activity.","indications":["Adjunctive treatment of partial-onset seizures in patients with epilepsy","Acute seizure management (intravenous bolus formulation)"],"catalyst":""},{"name":"Brivaracetam infusion","genericName":"Brivaracetam infusion","slug":"brivaracetam-infusion","phase":"phase_3","mechanism":"Brivaracetam binds to synaptic vesicle protein 2A (SV2A) to reduce neuronal excitability and prevent seizures.","indications":["Adjunctive treatment of partial-onset seizures in patients with epilepsy","Adjunctive treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy"],"catalyst":""},{"name":"CDP6038","genericName":"CDP6038","slug":"cdp6038","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"CDP7657","genericName":"CDP7657","slug":"cdp7657","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Certolizumab Pegol (CZP)","genericName":"Certolizumab Pegol (CZP)","slug":"certolizumab-pegol-czp","phase":"marketed","mechanism":"Certolizumab pegol is a TNF-alpha inhibitor that binds to and neutralizes tumor necrosis factor-alpha, reducing inflammatory signaling.","indications":["Rheumatoid arthritis","Crohn's disease","Psoriatic arthritis","Ankylosing spondylitis","Non-radiographic axial spondyloarthritis"],"catalyst":""},{"name":"Certolizumab pegol (CDP870)","genericName":"Certolizumab pegol (CDP870)","slug":"certolizumab-pegol-cdp870","phase":"phase_3","mechanism":"Certolizumab pegol is a TNF-alpha inhibitor that binds to and neutralizes tumor necrosis factor-alpha, reducing inflammatory signaling.","indications":["Rheumatoid arthritis","Crohn's disease","Psoriatic arthritis","Ankylosing spondylitis"],"catalyst":""},{"name":"Cetirizine drops","genericName":"Cetirizine drops","slug":"cetirizine-drops","phase":"marketed","mechanism":"Cetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on mast cells and basophils, preventing allergic cascade activation.","indications":["Allergic rhinitis (seasonal and perennial)","Chronic urticaria","Allergic conjunctivitis","Allergic asthma (adjunctive)"],"catalyst":""},{"name":"Cetirizine tablets","genericName":"Cetirizine tablets","slug":"cetirizine-tablets","phase":"marketed","mechanism":"Cetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on cells, reducing allergic symptoms.","indications":["Allergic rhinitis (seasonal and perennial)","Chronic urticaria","Allergic conjunctivitis"],"catalyst":""},{"name":"Kemstro","genericName":"Kemstro","slug":"kemstro","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Keppra XR (Levetiracetam XR)","genericName":"Keppra XR (Levetiracetam XR)","slug":"keppra-xr-levetiracetam-xr","phase":"phase_3","mechanism":"Levetiracetam reduces seizure activity by binding to synaptic vesicle protein SV2A and modulating neurotransmitter release.","indications":["Adjunctive therapy for partial-onset seizures in epilepsy","Adjunctive therapy for myoclonic seizures in juvenile myoclonic epilepsy","Adjunctive therapy for primary generalized tonic-clonic seizures"],"catalyst":""},{"name":"Keppra® extended release formulation - XR","genericName":"Keppra® extended release formulation - XR","slug":"keppra-extended-release-formulation-xr","phase":"phase_3","mechanism":"Levetiracetam binds to synaptic vesicle protein 2A (SV2A) to reduce neuronal excitability and prevent seizure propagation.","indications":["Adjunctive therapy for partial-onset seizures","Adjunctive therapy for myoclonic seizures in patients with juvenile myoclonic epilepsy","Adjunctive therapy for primary generalized tonic-clonic seizures"],"catalyst":""},{"name":"Levetiracetam (Keppra)","genericName":"Levetiracetam (Keppra)","slug":"levetiracetam-keppra","phase":"marketed","mechanism":"Levetiracetam reduces seizure activity by binding to synaptic vesicle protein SV2A and modulating neurotransmitter release.","indications":["Partial-onset seizures (adjunctive therapy)","Myoclonic seizures in patients with juvenile myoclonic epilepsy (adjunctive therapy)","Primary generalized tonic-clonic seizures (adjunctive therapy)"],"catalyst":""},{"name":"Levocetirizine (drug)","genericName":"Levocetirizine (drug)","slug":"levocetirizine-drug","phase":"marketed","mechanism":"Levocetirizine is a selective H1-receptor antagonist that blocks histamine binding to H1 receptors on mast cells and basophils, preventing allergic cascade activation.","indications":["Allergic rhinitis (seasonal and perennial)","Chronic urticaria","Allergic conjunctivitis"],"catalyst":""},{"name":"Levocetirizine oral solution","genericName":"Levocetirizine oral solution","slug":"levocetirizine-oral-solution","phase":"marketed","mechanism":"Levocetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses.","indications":["Allergic rhinitis (seasonal and perennial)","Chronic urticaria","Allergic conjunctivitis"],"catalyst":""},{"name":"Levocetirizine tablets","genericName":"Levocetirizine tablets","slug":"levocetirizine-tablets","phase":"phase_2","mechanism":"Selective histamine H1 receptor antagonist","indications":["Allergic rhinitis","Chronic urticaria"],"catalyst":""},{"name":"Methylphenidate Extended Release Capsules","genericName":"Methylphenidate Extended Release Capsules","slug":"methylphenidate-extended-release-capsules","phase":"marketed","mechanism":"Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity in the brain by blocking their reuptake at the presynaptic neuron.","indications":["Attention-deficit/hyperactivity disorder (ADHD) in children and adults","Narcolepsy"],"catalyst":""},{"name":"Neupro®","genericName":"Neupro®","slug":"neupro","phase":"marketed","mechanism":"Neupro is a dopamine agonist that stimulates dopamine receptors in the brain to restore dopamine signaling in patients with Parkinson's disease and restless legs syndrome.","indications":["Parkinson's disease (early-stage and advanced)","Restless legs syndrome (moderate to severe)"],"catalyst":""},{"name":"Niravam","genericName":"Niravam","slug":"niravam","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo + Methotrexate (MTX)","genericName":"Placebo + Methotrexate (MTX)","slug":"placebo-methotrexate-mtx","phase":"phase_3","mechanism":"Methotrexate inhibits dihydrofolate reductase to suppress DNA synthesis and reduce inflammatory immune cell proliferation.","indications":["Rheumatoid arthritis","Other autoimmune/inflammatory conditions (specific indication dependent on trial protocol)"],"catalyst":""},{"name":"Placebo to Pentoxifylline oral","genericName":"Placebo to Pentoxifylline oral","slug":"placebo-to-pentoxifylline-oral","phase":"phase_3","mechanism":"Pentoxifylline improves blood flow and reduces blood viscosity by increasing red blood cell flexibility and decreasing platelet aggregation.","indications":["Intermittent claudication (peripheral arterial disease)","Diabetic angiopathies","Trophic disorders and ischemic ulcers"],"catalyst":""},{"name":"Placebo-Cetirizine","genericName":"Placebo-Cetirizine","slug":"placebo-cetirizine","phase":"phase_3","mechanism":"Cetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in the central and peripheral nervous systems.","indications":["Allergic rhinitis","Chronic urticaria","Allergic conjunctivitis"],"catalyst":""},{"name":"Placebo-Levocetirizine","genericName":"Placebo-Levocetirizine","slug":"placebo-levocetirizine","phase":"phase_3","mechanism":"Levocetirizine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses.","indications":["Allergic rhinitis","Chronic urticaria"],"catalyst":""},{"name":"SPM 927","genericName":"SPM 927","slug":"spm-927","phase":"phase_3","mechanism":"SPM 927 is a selective T-type calcium channel blocker that reduces neuronal excitability and seizure activity.","indications":["Epilepsy (focal seizures)","Generalized seizures"],"catalyst":""},{"name":"SPM 929","genericName":"SPM 929","slug":"spm-929","phase":"phase_3","mechanism":"SPM 929 is a selective serotonin reuptake inhibitor (SSRI) that works by increasing the levels of serotonin in the brain.","indications":["Major depressive disorder","Generalized anxiety disorder"],"catalyst":""},{"name":"SSRI/SNRI","genericName":"SSRI/SNRI","slug":"ssri-snri","phase":"marketed","mechanism":"SSRIs and SNRIs increase serotonin (and norepinephrine for SNRIs) in the brain by blocking their reuptake from the synaptic cleft, thereby enhancing mood regulation and emotional processing.","indications":["Major depressive disorder","Generalized anxiety disorder","Panic disorder","Social anxiety disorder","Obsessive-compulsive disorder"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFBsLXFfRHMwWTNMZEdlN25rM25JNnNYRTV5aTBKRTA0VXl0bTZleDctTnVzTWJmODNLc256N0hGSzY2TTRUcXNSemxJdnNWVkZGZW1j?oc=5","date":"2026-04-03","type":"deal","source":"FirstWord Pharma","summary":"UCB breaks into T-cell engager space with $1.2B Antengene deal - FirstWord Pharma","headline":"UCB breaks into T-cell engager space with $1.2B Antengene deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxObEYtdGg2bGdPRkg2Ql9Pb0U5d3NBUW04eG1QdWVia2Y1djVfcngzaVJxalFscVN1UWd2QWNHMlk2N3dEc28xY0xkRVJDb1JMd09qVU9JVDJxSTQxbXZEWDFsRFpZaUgtNTVMYnFVSEhLZ2M0UWJCNlJKMXJiMjV2Yk1JWHJhTWpwRm9aTFQ5ckx2b2VqUjlPZXBKdmdlYmc?oc=5","date":"2026-03-25","type":"pipeline","source":"AP News","summary":"Belgian drugmaker UCB to invest $2B in suburban Atlanta plant, adding 330 jobs - AP News","headline":"Belgian drugmaker UCB to invest $2B in suburban Atlanta plant, adding 330 jobs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPeHVBaXV0N0REOEh4TTBORnpUeW9mczBCNDB4Q012U3FHSWE1NERWejNkNEQteDJPZEMxNzBCVk8xa0MyMnoxS3N1YnAtZDZKblQyd1cxSWxfZjB0Ti1HbjYtYThzV3QzTkhsSnN5cFd6Q2gwbGlsVEdSTlA4ZGVuTXNhc1JWNDVudjZwcjFjTlRrY1pJUjlBOEJSa0NnenJxZlhfY09OU3JZUUYtbldEVFVn?oc=5","date":"2026-03-25","type":"pipeline","source":"Pharmaceutical Technology","summary":"UCB banks on Georgia for $2bn biologics manufacturing facility - Pharmaceutical Technology","headline":"UCB banks on Georgia for $2bn biologics manufacturing facility","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOZk9Ob1E1XzVrcDdFN3NsNDdEU000UXd3U0tQNTEzenJ6dXgzOUg0dVJZaEM5Q0d1Z1gtNlhRRkxTSTViWnExRWZjNFdUNXlrVGtPakpGdEtSSzhzZzF5MHhlNDNYY0d5dm8xZzd4cWZsOUJ1M2IwX2VUWll6U3d4LUN3X2wzcmRrem1XbWJWc0V2OU5FQkhtV2ZycVoxekNyTll3VG1FZWswelVRaHVJ?oc=5","date":"2026-03-25","type":"pipeline","source":"Contract Pharma","summary":"UCB to Build New U.S. Biologics Manufacturing Facility in Georgia - Contract Pharma","headline":"UCB to Build New U.S. Biologics Manufacturing Facility in Georgia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOVmM1Y0tSNTg4b2t3OUlDLTBkM1kyTldjLXFkazByNmpTcWRoVnhnLXlWUlAwSFZIXzBpTWViRFB1OXpZMURtdVJnM3dyZlpHaXdJbWptNld3enAwczdoSFZOTktieUtJZ0d6YUZPUXpHb25WLWx1aTF6Y0ZkN2R2V180TjJEX3ZNTmYwX3dITmprT05ZSFlERTZBSVl4NWs?oc=5","date":"2026-03-24","type":"earnings","source":"Fierce Pharma","summary":"UCB unveils plan to build $2B biologics plant near its US headquarters in Atlanta - Fierce Pharma","headline":"UCB unveils plan to build $2B biologics plant near its US headquarters in Atlanta","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOS0sweEFsOVlZdXJUMlFsUDhWN2dlWTRkdldUZHl6bG1fWXhnd0ptSDAwYVR1aFFpNk4wYndRM19Qanl5d2JlczdoMzNfZ1VEUXk4V1FORjNDa0xIU3JfeVd3bUxITkc4cWFMWTFGYXpncGluYU5fX3lIUTJvS0NXdzNzTThlSy0tUjhpV0l6MThoNEJyazZ4dzktZ0lUb25KVGpHOXJ5QlNzVHJVWVZnRWRNSVIyenp5TlBabzlKb0VKQQ?oc=5","date":"2026-03-24","type":"pipeline","source":"CBS News","summary":"Biopharmaceutical company UCB names Gwinnett County site of 1st U.S. biologics facility - CBS News","headline":"Biopharmaceutical company UCB names Gwinnett County site of 1st U.S. biologics facility","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxONE81ZHFVaVY4V0g1ejRMb1FUX0VhM2RGT3hrQUJBc1FuUXpJampJUU02cEl2VmhPSXV4TGEtQ2lucmgydThHQnVFMU1LRG13U3dTaGpEa0pta2llRGR1WFNFbjJ4eWxHeFozVUlCQVc1XzZjRnE3UFEyY2ladTkybHFERGxCaDFGTUpEMDJjU3h4clXSAZgBQVVfeXFMUHl4dXJVQlFMc2VxN3hQXzE4QkpqZjAtdjRTQ1htTzBHVFZkUGZDc2RVR05tLTFOR0xrUUprM2tTWFFWQ1U3ZnZaanpqNGFiNmhPRlg2SDJSemhNYWl5Y3BzVjRhWWZ2ZmVVSTZWVzBYN25IbGVyc3NNaEx4TTJWa2p6c0liTUxUd2FEbWRQeS1VXzFSZENWcms?oc=5","date":"2026-03-24","type":"pipeline","source":"The Center Square","summary":"Belgian pharma company making $2B investment in Georgia - The Center Square","headline":"Belgian pharma company making $2B investment in Georgia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNX0xCd0ttbDVLdm5FQXBPM2E1UDhzSm1BMTNuMXN0OUQ4bUd4M01GLUxqMFctdHVHeWNwQUoxS18ybG5EZF91V3JDbG00bjFsLW1ETjFVZDJWc09iOFFhaWR2QmdLZTZpeG1wTWhzd3JXVWJXYmtpWFM4U2ctbW9oMXd4QkRkYXVHX0lJQ0VrVTUzbnk2aGcyeWJoZ1RLRTQyM3VtRkMwUjV6U2s2VnBBMmdVTDVJX19kb1JmdDJrSS1NNWkxMGVrUU03eEl5MHc?oc=5","date":"2026-03-04","type":"deal","source":"European Pharmaceutical Review","summary":"UCB signs $1.1bn to autoimmune collaboration with Chinese biotech Antengene - European Pharmaceutical Review","headline":"UCB signs $1.1bn to autoimmune collaboration with Chinese biotech Antengene","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNb0tiUmpQMmZrWDJzbnhkc2dQSlVmQk5GdHFpeUlieDNKRTg3RU5vOEZoQVZaQ204dk9qVGp4YS13Vlg5R2ZQa1dJcndKN1FSWmRlNlNjRnhfcG05YlY1Tk9LUTlOeDk5VjF1Y1hBMXNBZ1ViMTNrOWdGai1fUEVSZ1Ffb2tqWEtGQXowUmc5QURPcEdndjRtcjlEVUZjTzV4?oc=5","date":"2026-02-26","type":"earnings","source":"The Pharma Letter","summary":"UCB posts strong fourth quarter finish as profit surges - The Pharma Letter","headline":"UCB posts strong fourth quarter finish as profit surges","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTE9RTXdFS015ZWszM0JMejBqWDFOY3l1YmpOZUdsNHJkMDZEcVRZNHJlenRjb3VkWkZyb3JkYzFTQnA5YWwyazk1Q1FSY3NSZGhCWUNkVTZYNVpkdDN2ZUhiVW5yWnIxZmk4NmtWcThwMA?oc=5","date":"2026-02-20","type":"pipeline","source":"medwatch.com","summary":"Zealand Pharma nominates UCB veteran for its board of directors - medwatch.com","headline":"Zealand Pharma nominates UCB veteran for its board of directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxNRDZSdTB0WWxNRUhRYVg0WEh0aHUxaERDZ0Q2cDZ3OWlFbkU4aG5oQXpsc3I1R2xZT3Y2elRsSDVKeTRWWk5Cc213eUNkeXlQZ0RFbGJiaTd1N2VyWDZYRWRGMzBVREs2VHdYRE4yczRVQnRKVkZ0c0ZiVEVTdzQ4c281Sm8tcFYxbFZhdjhZeTU5NnJESm8xOGZUeTJCZktScHZLcFBwdnhWQ3U2dGtQaUZuREhPdjFUWXMtNzhvdDA5UDkwODdSbUs3Zl9Hb2h5S2lvR1RBUUNjZlMtWlh3R2N1eXFfQQ?oc=5","date":"2025-10-01","type":"deal","source":"Business Wire","summary":"Tanner Pharma Group and UCB Pharma Initiate Partnership for Epilepsy Program in Southeast Asia - Business Wire","headline":"Tanner Pharma Group and UCB Pharma Initiate Partnership for Epilepsy Program in Southeast Asia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPbHE0Mm9YMGxVUkZ3dDZDNDA1Wnl1VndPOTBZSWNhQ19zbE1NMjA5TDJnc3pEdHR1Mnd5WU5UV1JlSEFQVWI2a1EwNVVjNmx6MV9yajVaZjRqbHRFdEtLdndHVEM4dVVvTEpaaVFlYjF6cHhzLXBvcVdCMDlyMGZqRjFMZ3k3Vk9DbWNDV2tiRU9kN3hjLS14Qk9vaU1pay1vX0ROZmlkenZ6akgwM3hMTzFHcGEtYldmSHVIQmpvME50NjctWFpv?oc=5","date":"2025-06-12","type":"pipeline","source":"UCB","summary":"UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity - UCB","headline":"UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity","sentiment":"neutral"}],"patents":[],"drugCount":27,"phaseCounts":{"phase_3":13,"phase_2":2,"phase_1":1,"marketed":11},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}